Basilea Pharmaceutica AG GAAP EPS of CHF 3.14, revenue of CHF 232.4M
Source: SeekingAlpha
2026-02-17 08:53:02 ET
More on Basilea Pharmaceutica AG
- Basilea partners with Phare Bio to deploy generative AI for antibiotic discovery
- Seeking Alpha’s Quant Rating on Basilea Pharmaceutica AG
- Historical earnings data for Basilea Pharmaceutica AG
- Financial information for Basilea Pharmaceutica AG
Read the full article on Seeking Alpha
For further details see:
Basilea Pharmaceutica AG GAAP EPS of CHF 3.14, revenue of CHF 232.4M
Basilea Pharm Ag Akt Shs
NASDAQ: BPMUF
BPMUF Trading
662.89% G/L:
$74 Last:
100 Volume:
$74 Open:
BPMUF Latest News
February 25, 2026 01:15:00 am
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
February 17, 2026 01:15:00 am
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
February 09, 2026 01:15:00 am
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
